Core Insights - LifeMD, Inc. has announced a collaboration with Novo Nordisk to provide Ozempic at a reduced price of $499 per month for eligible self-pay patients [1][2] - The integration with NovoCare Pharmacy allows access to all FDA-approved doses of Ozempic through LifeMD's virtual care platform [1][2] - The initiative aims to improve access to GLP-1 therapies for millions of Americans suffering from type 2 diabetes, a condition affecting approximately 36 million people in the U.S. [2][3] Company Overview - LifeMD is a leading provider of virtual primary care, offering telemedicine, laboratory and pharmacy services, and specialized treatment across over 200 conditions [4] - The company utilizes a vertically integrated digital care platform and a 50-state affiliated medical group to enhance access to high-quality and affordable care [4] Collaboration Details - The expanded collaboration with Novo Nordisk includes not only Ozempic but also Wegovy, enhancing LifeMD's ability to deliver competitive self-pay prices for FDA-approved GLP-1 therapies [2][3] - LifeMD's telehealth platform is also integrated with LillyDirect pharmacy to provide access to Zepbound (tirzepatide), further diversifying treatment options for patients [3]
LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk